Detalles de la búsqueda
1.
A prospective, randomized, double-blind, placebo-controlled multisite, parallel-group field study in dogs with osteoarthritis conducted in the United States of America evaluating bedinvetmab, a canine anti-nerve growth factor monoclonal antibody.
Vet Anaesth Analg
; 50(5): 446-458, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37541934
2.
A blinded, randomized, placebo-controlled trial of the safety of lokivetmab (ZTS-00103289), a caninized anti-canine IL-31 monoclonal antibody in client-owned dogs with atopic dermatitis.
Vet Dermatol
; 27(6): 505-e136, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27647513
3.
A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis.
Vet Dermatol
; 27(6): 478-e129, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27647569
4.
Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
Clin Cancer Res
; 15(11): 3856-65, 2009 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19470739
5.
Prognosis following surgical excision of canine cutaneous mast cell tumors with histopathologically tumor-free versus nontumor-free margins: a retrospective study of 31 cases.
J Am Anim Hosp Assoc
; 38(5): 458-66, 2002.
Artículo
en Inglés
| MEDLINE | ID: mdl-12220031
Resultados
1 -
5
de 5
1
Próxima >
>>